These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 27162345)

  • 1. Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation.
    Gross CC; Schulte-Mecklenbeck A; Rünzi A; Kuhlmann T; Posevitz-Fejfár A; Schwab N; Schneider-Hohendorf T; Herich S; Held K; Konjević M; Hartwig M; Dornmair K; Hohlfeld R; Ziemssen T; Klotz L; Meuth SG; Wiendl H
    Proc Natl Acad Sci U S A; 2016 May; 113(21):E2973-82. PubMed ID: 27162345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma.
    Gandoglia I; Ivaldi F; Carrega P; Armentani E; Ferlazzo G; Mancardi G; Kerlero de Rosbo N; Uccelli A; Laroni A
    Immunol Lett; 2017 Jan; 181():109-115. PubMed ID: 27919749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging role of IL-16 in cytokine-mediated regulation of multiple sclerosis.
    Skundric DS; Cruikshank WW; Montgomery PC; Lisak RP; Tse HY
    Cytokine; 2015 Oct; 75(2):234-48. PubMed ID: 25703787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
    Bielekova B; Catalfamo M; Reichert-Scrivner S; Packer A; Cerna M; Waldmann TA; McFarland H; Henkart PA; Martin R
    Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5941-6. PubMed ID: 16585503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.
    Börnsen L; Christensen JR; Ratzer R; Oturai AB; Sørensen PS; Søndergaard HB; Sellebjerg F
    PLoS One; 2012; 7(11):e47578. PubMed ID: 23226199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells.
    Carlsten M; Norell H; Bryceson YT; Poschke I; Schedvins K; Ljunggren HG; Kiessling R; Malmberg KJ
    J Immunol; 2009 Oct; 183(8):4921-30. PubMed ID: 19801517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity.
    Ott M; Avendaño-Guzmán E; Ullrich E; Dreyer C; Strauss J; Harden M; Schön M; Schön MP; Bernhardt G; Stadelmann C; Wegner C; Brück W; Nessler S
    J Neuroinflammation; 2019 Feb; 16(1):49. PubMed ID: 30808363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical roles of co-activation receptor DNAX accessory molecule-1 in natural killer cell immunity.
    Xiong P; Sang HW; Zhu M
    Immunology; 2015 Nov; 146(3):369-78. PubMed ID: 26235210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD155 on HIV-Infected Cells Is Not Modulated by HIV-1 Vpu and Nef but Synergizes with NKG2D Ligands to Trigger NK Cell Lysis of Autologous Primary HIV-Infected Cells.
    Davis ZB; Sowrirajan B; Cogswell A; Ward JP; Planelles V; Barker E
    AIDS Res Hum Retroviruses; 2017 Feb; 33(2):93-100. PubMed ID: 27296670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis.
    Laroni A; Armentani E; Kerlero de Rosbo N; Ivaldi F; Marcenaro E; Sivori S; Gandhi R; Weiner HL; Moretta A; Mancardi GL; Uccelli A
    J Autoimmun; 2016 Aug; 72():8-18. PubMed ID: 27157273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood CD4+ T lymphocytes from multiple sclerosis patients are characterized by higher PSGL-1 expression and transmigration capacity across a human blood-brain barrier-derived endothelial cell line.
    Bahbouhi B; Berthelot L; Pettré S; Michel L; Wiertlewski S; Weksler B; Romero IA; Miller F; Couraud PO; Brouard S; Laplaud DA; Soulillou JP
    J Leukoc Biol; 2009 Nov; 86(5):1049-63. PubMed ID: 19696154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis.
    Rodríguez-Martín E; Picón C; Costa-Frossard L; Alenda R; Sainz de la Maza S; Roldán E; Espiño M; Villar LM; Álvarez-Cermeño JC
    Clin Exp Immunol; 2015 May; 180(2):243-9. PubMed ID: 25565222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis.
    Sheridan JP; Zhang Y; Riester K; Tang MT; Efros L; Shi J; Harris J; Vexler V; Elkins JS
    Mult Scler; 2011 Dec; 17(12):1441-8. PubMed ID: 21807759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The regulatory role of natural killer cells in multiple sclerosis.
    Takahashi K; Aranami T; Endoh M; Miyake S; Yamamura T
    Brain; 2004 Sep; 127(Pt 9):1917-27. PubMed ID: 15229129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients.
    Sanchez-Correa B; Gayoso I; Bergua JM; Casado JG; Morgado S; Solana R; Tarazona R
    Immunol Cell Biol; 2012 Jan; 90(1):109-15. PubMed ID: 21383766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
    Sellner J; Koczi W; Harrer A; Oppermann K; Obregon-Castrillo E; Pilz G; Wipfler P; Afazel S; Haschke-Becher E; Trinka E; Kraus J
    Clin Exp Immunol; 2013 Sep; 173(3):381-9. PubMed ID: 23611040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD56brightCD16- NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+ T Cell Proliferation.
    Morandi F; Horenstein AL; Chillemi A; Quarona V; Chiesa S; Imperatori A; Zanellato S; Mortara L; Gattorno M; Pistoia V; Malavasi F
    J Immunol; 2015 Aug; 195(3):965-72. PubMed ID: 26091716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
    Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
    Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases.
    Chan CJ; Andrews DM; McLaughlin NM; Yagita H; Gilfillan S; Colonna M; Smyth MJ
    J Immunol; 2010 Jan; 184(2):902-11. PubMed ID: 20008292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.